Advances in shock wave lithotripsy for kidney stone management

Australia records one of the highest rates of urolithiasis in the developed world, with regional studies suggesting a lifetime prevalence approaching fifteen per cent in some outpatient cohorts. The combination of a hot continental climate, episodic dehydration, and dietary patterns rich in animal protein and salt contributes to a steady stream of patients presenting with renal colic to emergency departments in Sydney, Brisbane, and Perth. For most uncomplicated cases, extracorporeal shock wave lithotripsy remains a first-line intervention alongside flexible ureteroscopy.

The original Dornier HM3 lithotripter, introduced into Australian teaching hospitals during the late 1980s, transformed how urologists approached upper-tract calculi. Its water-bath coupling and electrohydraulic spark-gap energy source produced consistent fragmentation but required general or regional anaesthesia and a dedicated endourology suite. Contemporary devices are markedly smaller, use electromagnetic or piezoelectric energy, and allow treatment in ambulatory day-surgery settings, an arrangement that aligns well with the workflow of Australian public hospitals operating under activity-based funding.

For clinicians seeking broader context on integrated urological care pathways, international health resources offer additional perspectives. The goal of this overview is to summarise where shock wave lithotripsy sits within current practice, where the technology is heading, and how Australian urologists are using it in 2025.

The evolution of extracorporeal shock wave lithotripsy

The first clinical application of focused acoustic energy to fragment renal calculi occurred in Munich in 1980, and within five years lithotripters had spread to North America, Europe, and Australasia. The early machines were large, expensive, and required substantial infrastructure. The University of Melbourne's department of surgery, in collaboration with St Vincent's Hospital, was among the first Australian sites to acquire a clinical unit, and many senior Australian urologists trained on this platform.

The transition from first-generation to second- and third-generation lithotripters brought several practical improvements. Modern units feature integrated fluoroscopy and inline ultrasound, allowing real-time targeting without patient repositioning. Coupling has moved from water baths to dry, gel-pad systems that are quicker to set up and easier to clean between cases. The reduction in anaesthesia requirements, often only light sedation with short-acting opioids, has made lithotripsy feasible in standalone day-surgery units such as those operating in the outer suburbs of Adelaide and Geelong.

The Urological Society of Australia and New Zealand has published position statements endorsing lithotripsy as a treatment option for renal stones up to two centimetres, particularly in the proximal ureter and renal pelvis, where stone-free rates after a single session can exceed seventy per cent for non-cystic calculi. The society also highlights the importance of audit, recommending that units maintain prospective databases of treatment outcomes, a standard now embedded in many metropolitan centres.

Modern lithotripter design and acoustic principles

Contemporary lithotripters generate shock waves through three principal mechanisms. Electromagnetic sources produce a flat coil and membrane arrangement, generating a focused pressure pulse with high reproducibility. Electrohydraulic systems use an underwater spark to create a spherical wave that is then reflected and concentrated. Piezoelectric arrays, comprising hundreds of small crystals arranged on a dish, create converging pressure fronts with relatively low skin pain scores.

A key advance has been the ability to modulate the focal zone. Older lithotripters had a narrow, high-pressure focus that maximised fragmentation but also increased the risk of parenchymal injury. Newer devices offer adjustable apertures and variable pressure profiles, allowing operators to trade peak pressure for a wider focal volume. This is particularly useful in patients with atypical anatomy, such as those with horseshoe kidneys or pelvic kidneys encountered in complex caseloads at Royal North Shore Hospital in Sydney.

Coupling quality has emerged as an under-recognised determinant of success. Air pockets between the therapy head and skin can attenuate the pressure wave substantially. Operators now routinely use ultrasound gel warmed to body temperature, and some centres in Melbourne have adopted automated gel-pad systems that maintain a stable interface throughout the procedure. The combination of reproducible coupling, real-time imaging, and adjustable focal geometry has narrowed the historical gap between the original Dornier HM3 and modern compact units.

Patient selection and preoperative planning

Appropriate selection remains the strongest predictor of a successful outcome. Stones between five and twenty millimetres in the renal pelvis or proximal ureter, with Hounsfield units below roughly one thousand, generally respond well. Stones in the lower pole are more controversial, with stone-free rates falling when the infundibulopelvic angle is steep or the calyceal neck is narrow. Australian radiologists routinely include these measurements in their pre-procedure reports, and many units now use three-dimensional reconstruction from non-contrast CT to plan the optimal access angle.

Body habitus also matters. The focal depth of most lithotripters sits between twelve and sixteen centimetres from the skin surface, and patients with a very high body mass index may not be suitable. For patients living in regional and remote parts of Queensland, Western Australia, and the Northern Territory, distance from a lithotripsy service adds another layer of complexity. Outreach services run by urologists from Brisbane and Perth have tried to bridge this gap, but the tyranny of distance still affects follow-up imaging and the timely identification of residual fragments.

Pregnancy, untreated coagulopathy, and uncontrolled urinary tract infection are absolute contraindications. Aortic and renal artery aneurysms near the planned focal zone also exclude treatment, as do some skeletal deformities that prevent adequate positioning. Pre-procedural urine culture, full blood count, and a recent CT within twelve weeks are now standard in most Australian centres, supported by Medicare Benefits Schedule rebates that encourage this workup.

Anaesthesia, analgesia, and perioperative care

The shift toward minimal sedation has been one of the defining changes in modern lithotripsy practice. Most Australian units now use a combination of an intravenous short-acting opioid, such as fentanyl or alfentanil, with a low-dose benzodiazepine, supplemented by inhaled nitrous oxide where available. Day-surgery admission under this protocol is common, particularly in private hospitals along the eastern seaboard where bed capacity is constrained.

For children and anxious adults, general anaesthesia with a laryngeal mask airway remains an option and allows breath-hold techniques to minimise stone movement during firing. Some centres in Melbourne have reported excellent outcomes with patient-controlled analgesia, in which the patient triggers shocks at comfortable intervals, an approach that may reduce total energy delivered while maintaining fragmentation.

Postoperative care emphasises early mobilisation, adequate hydration, and strainer analysis of passed fragments. Alpha-blockers such as tamsulosin are routinely prescribed off-label as medical expulsive therapy, supported by data from the ANZUP-led SUSPEND trial and subsequent meta-analyses. Patients are typically reviewed at six to twelve weeks with a non-contrast CT to confirm clearance, and those with residual fragments larger than four millimetres are considered for re-treatment or alternative intervention.

Clinical outcomes and complication management

Contemporary stone-free rates after a single lithotripsy session range from sixty to eighty per cent for stones in favourable locations, with overall rates approaching ninety per cent after two sessions. Variations in outcome depend on stone size, composition, density, and operator experience. Cystine and brushite stones are notoriously resistant, while calcium oxalate dihydrate and uric acid stones fragment readily when the patient is well prepared with adequate analgesia and coupling.

Complications are uncommon but important to recognise. Steinstrasse, a column of fragments within the ureter, occurs in five to ten per cent of treatments and may require urgent ureteroscopy if associated with sepsis or severe pain. Subcapsular haematoma, while rare, has been reported across Australian centres, and patients on antiplatelet or anticoagulant therapy need careful planning, often involving temporary cessation under haematology guidance. Readers interested in reviewing the full range of recent evidence can explore the latest journal issues for original articles and case series covering these topics.

Transient haematuria and dysuria are expected and self-limiting, but persistent fever or rigors should prompt urgent assessment for obstructive pyelonephritis. Australian data suggest that with appropriate antibiotic prophylaxis, the rate of post-procedural urosepsis remains below two per cent, even in units that treat a high volume of complex stones.

Emerging technologies and future horizons

Several developments are reshaping the field. Burst wave lithotripsy, which uses low-amplitude sinusoidal pulses rather than single shock waves, has shown promise in preclinical work for fragmenting stones into small, passable pieces with potentially less tissue injury. Although commercial systems are not yet available in Australia, collaborative research with centres in Sydney and Brisbane is evaluating prototype units in vitro.

Artificial intelligence is being integrated into targeting and treatment planning. Algorithms trained on thousands of stone cases can now predict fragmentation success based on CT-derived features, and some lithotripters include software that suggests optimal focal positioning. Beyond lithotripsy, AI is influencing broader urological prescribing, with several recent Australian studies exploring the role of machine learning in identifying patients at risk of recurrent stones or complications of related conditions such as pharmacotherapies for overactive bladder.

Combination approaches are also gaining traction. Pre-treatment with low-dose tamsulosin, intraoperative ultrasound elastography to confirm coupling, and postoperative chemolysis with potassium citrate for uric acid stones represent an integrated care model that several Australian teaching hospitals are now piloting. As imaging, energy delivery, and pharmacology continue to advance, shock wave lithotripsy is likely to remain a cornerstone of kidney stone management well into the next decade.

Readers and clinicians can stay current with the field by accessing the full archive at the journal's website, where open-access articles, in-press manuscripts, and guidelines are freely available. Authors planning to contribute to the next issue are encouraged to consult the author guidelines and submit original research, case reports, or reviews that reflect the breadth of contemporary urological practice in Australia and the wider region.